MedOPP107
- 4 marzo, 2019
- /
- 0
Multicenter, open-label, phase II trial to evaluate the efficacy and safety of naI-IRI for progressing brain metastases in patients with HER2 negative breast cancer.
Calle Severo Ochoa, 35
Parque Tecnol?gico de Andaluc?a (PTA) Campanillas,
M?laga 29590
(+34) 951 440 260
Fax: (+34) 951 440 263